Novavax announced they are shifting focus from direct commercial operations to R&D and licensing. The strategy relies heavily on their partnership with Sanofi. They recently transferred U.S. marketing authorization for their COVID vaccine to Sanofi, which triggered a $25 million milestone payment. 2025 revenue guidance was increased, but the long-term outlook now depends on partners meeting commercial targets rather than direct sales.